The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Perspective
Patient safety is the top priority of every caregiver. Hospitals and health systems never stop searching for ways to improve quality, performance and results…
Blog
The greatest success story of the 20th century is longevity. This is especially true in the United States, where average life expectancy at birth rose by more…
Headline
The AHA the week of July 8 released its Quality Collective Report, which explores quality, safety and performance improvement strategies and insights from…
Headline
In a new “Safety Speaks” conversation, Harry S. Smith, board chair of Valley Health System and member of the AHA Committee on Governance, discusses how Valley…
Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
The Centers for Disease Control and Prevention June 25 issued a Health Alert Network Health Advisory about an increased risk of dengue virus infections in the…